PYXS insider transaction filings
Pyxis Oncology, Inc. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-08. Screen PYXS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 35,000 shares, $107,100 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: sale of 35,000 shares @ $3.06 ($107,100) by Dupont Jakob, filed 2026-07-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Dupont Jakob — Director | 2 | — | 1 leg · 35,000 sh · $107,100 | 3 |
| Civik Thomas — CEO & Chairman of the Board, Director | 2 | — | — | 2 |
Recent Form 4 filings — Pyxis Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Civik Thomas — CEO & Chairman of the Board, Director | Grant/award (A): 2,503,050 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Dupont Jakob — Director | Grant/award (A): 46,000 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Civik Thomas — Interim CEO, Director | Grant/award (A): 250,956 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Dupont Jakob — Director | Option exercise (M): 35,000 @ $1.60 · Sale (S): 35,000 @ $3.06 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Wadhane Jitendra — Prin Fin & Acct Officer | Grant/award (A): 109,461 @ $0 · Grant/award (A): 262,635 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Palani Santhosh — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Cline Darren S — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | HUMPHREY RACHEL — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | HUMPHREY RACHEL — Director | Sale (S): 1,400 @ $0.97 · Sale (S): 200 @ $0.97 · Sale (S): 13,896 @ $1.03 | EDGAR |
| 2026-03-25 | 4 | Dupont Jakob — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Metzger Michael A — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Lewis-Hall Freda C — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | FLAVIN JOHN L — Director | Grant/award (A): 45,867 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Civik Thomas — Interim CEO, Director | Grant/award (A): 690,131 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Wadhane Jitendra — SVP, Chief Accounting Officer | Grant/award (A): 263,782 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Palani Santhosh — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Connealy Pamela Ann — CFO & COO | Grant/award (A): 414,163 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Sullivan Lara — President ,CEO & CMO, Director | Grant/award (A): 918,308 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Civik Thomas — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Cline Darren S — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | HUMPHREY RACHEL — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Dupont Jakob — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Metzger Michael A — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | Lewis-Hall Freda C — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2025-04-02 | 4 | FLAVIN JOHN L — Director | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2024-12-23 | 4 | Connealy Pamela Ann — CFO & COO | Grant/award (A): 310,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Wadhane Jitendra — SVP, Chief Accounting Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Sullivan Lara — Chief Executive Officer, Director | Grant/award (A): 1,135,000 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | Connealy Pamela Ann — CFO & COO | Purchase (P): 5,450 @ $2 · Purchase (P): 83,400 @ $1.96 | EDGAR |
| 2024-06-10 | 4 | Metzger Michael A — Director | Grant/award (A): 70,683 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Palani Santhosh — Director | Grant/award (A): 6,000 @ $0 | EDGAR |
| 2024-03-28 | 4 | Connealy Pamela Ann — CFO & COO | Grant/award (A): 328,710 @ $0 | EDGAR |
| 2024-03-28 | 4 | Wadhane Jitendra — SVP, Chief Accounting Officer | Grant/award (A): 131,484 @ $0 | EDGAR |
| 2024-03-28 | 4 | Sullivan Lara — Chief Executive Officer, Director | Grant/award (A): 1,071,242 (derivative) @ $3.83 | EDGAR |
| 2024-03-28 | 4 | Civik Thomas — Director | Grant/award (A): 44,024 (derivative) @ $3.83 | EDGAR |
| 2024-03-28 | 4 | Cline Darren S — Director | Grant/award (A): 35,219 @ $0 | EDGAR |
| 2024-03-28 | 4 | HUMPHREY RACHEL — Director | Grant/award (A): 38,741 @ $0 | EDGAR |
| 2024-03-28 | 4 | Dupont Jakob — Director | Grant/award (A): 38,741 @ $0 | EDGAR |
| 2024-03-28 | 4 | Lewis-Hall Freda C — Director | Grant/award (A): 35,219 @ $0 | EDGAR |
| 2024-03-28 | 4 | FLAVIN JOHN L — Director | Grant/award (A): 35,219 @ $0 | EDGAR |
| 2024-03-13 | 4 | Palani Santhosh — Director | Grant/award (A): 69,760 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Kobayashi Ken — Chief Medical Officer | Grant/award (A): 443,514 (derivative) @ $0 · Grant/award (A): 110,878 (derivative) @ $0 | EDGAR |
Recent 8-K events — Pyxis Oncology, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-04-30 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-02-06 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PYXS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →